Open AccessBlack Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab
Author(s) -
Charlotte Hawkins,
Pedro Barata,
Patrick Cotogno,
Gaynelle Davis,
Ellen B. Jaeger,
Elisa M. Ledet,
Patrick J. O. Miller,
Brian Lewis,
Oliver Sartor,
Jodi Lyn Layton
Publication year - 2022
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1093/oncolo/oyac203
Subject(s) - medicine , enzalutamide , clinical endpoint , prostate cancer , oncology , abiraterone acetate , hormonal therapy , avelumab , prostate specific antigen , cancer , urology , clinical trial , immunotherapy , androgen deprivation therapy , nivolumab , androgen receptor
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom